Skip to main content
OpenTrials
Completed

NCT Number: NCT03715868

Pre-operative Short-term Administration of a Formula Diet Containing a Non-milk-derived Protein Source for Prevention of Acute Kidney Injury After Cardiac Surgery

Cardiac surgery is associated with a high risk of postoperative AKI with significant morbidity and mortality. To date, no preventive or therapeutic measures exist to prevent this. According to the data from animal trials, a preoperative diet with a deficiency of milk-derived proteins may be a new preventive measure in this context.

This trial will investigate whether one week of changing the diets protein source to a non-milk-derived one prior to surgery effectively induces renal protection from post-surgery AKI in humans. Patients undergoing elective cardiac surgery are randomized into two arms. In the non-milked-derived based diet arm, patients receive an appropriate formula diet based on a protein source other than milk derived proteins. In the control arm, patients are provided with a formula diet based on milk-protein. Total amount of calories and proteins is not restricted and - due to randomization - assumed not to be significantly different between the two arms.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital of Cologne

Cologne, 50937, Germany

About this study

Cardiac surgery is associated with a high risk of postoperative AKI with significant morbidity and mortality. Acute kidney injury (AKI) constitutes a significant complication in hospitalized patients with an incidence of about 30%. Depending on existing comorbidities, a mortality of up to 60% occurs in critically ill or postoperative patients with AKI. To date, no preventive or therapeutic measures exist to prevent this. According to the data from animal trials, a preoperative diet low in sulfur-containing amino acids may be a new preventive measure in this context.

This trial will investigate whether one week of changing the diets protein source to a non-milk-derived one prior to surgery effectively induces renal protection from post-surgery AKI in humans. Patients undergoing elective cardiac surgery are randomized into two arms.

In the non-milked-derived based diet arm, patients receive an appropriate formula diet based on a protein source other than milk derived proteins. The formula diet replaces the regular diet completely from day -7 until the scheduled cardiothoracic surgery. The amount of formula diet is based on individual calculations to cover the patients daily energy demand.

In the control arm, patients are provided with a formula diet based on milk-protein, accordingly. Total amount of calories and proteins is not restricted and - due to randomization - assumed not to be significantly different between the two arms.

The primary endpoint of the clinical trial is to investigate whether a preoperative diet with a deficiency of milk-derived proteins leads to a reduction of AKI incidence within 72 hours after surgery. AKI is defined according to 'Kidney Disease: Improving Global Outcomes' (KDIGO) classification as an increase in serum creatinine of ≥0.3 mg/dl within 48 hours, or an increase of serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days, or a reduction of urine output to <0.5ml/kg/hour for more than 6 hours.

Baseline creatinine will be assessed prior to the start of the surgical procedure. The time frame for the following assessments with respect to the primary endpoint will be 72 hours from the onset of ischemia (cross-clamping). Blood samples will be obtained at 24 hours, 48 hours, and 72 hours after cross-clamping. Hourly urine output will be assessed as long as a Foley-catheter is in place.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women ≥50 years of age
  • Caucasian ethnicity
  • Scheduled cardiac surgery with use of the heart-lung machine with a lead time of at least 9 days
  • Written informed consent

Exclusion criteria

  • Chronic renal replacement therapy
  • Status post kidney transplantation
  • Vegetarian lifestyle
  • BMI <18.5 kg/m2
  • Calorie-reduced diet within the preceding 4 weeks
  • Underlying wasting disease
  • Uncontrolled local or systemic infection
  • Contraindication for enteral nutrition
  • Known allergy to or intolerance of the ingredients of the formula diets used
  • Pregnancy or breastfeeding
  • Absence of safe contraceptive measures or non-occurrence of menopause (in women)
  • Participation in other interventional trials
  • Persons who are in a dependency/employment relationship with the investigators
  • Accommodation in an institution by judicial or administrative order.

Treatment and study plan

Non-milked derived protein source formula diet

Other

Formula diet based on a non-milked derived protein source

Primary outcomes

  1. AKI incidence within 72 hours according KDIGO classification after induction of ischemia ('cross clamping') in comparison to baseline values

    Time frame: Pre-operative baseline day of surgery to 72 hours after induction of ischemia

    The primary endpoint of the clinical trial is to investigate whether a preoperative diet with a non-milked derived protein source leads to a reduction of AKI incidence within 72 hours after surgery. AKI is defined according to KDIGO as an increase in serum creatinine of ≥0.3 mg/dl within 48 hours, or an increase of serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days, or a reduction of urine output to <0.5ml/kg/hour for more than 6 hours.

    Baseline creatinine will be assessed prior to the start of the surgical procedure. The time frame for the following assessments with respect to the primary endpoint will be 72 hours from the onset of ischemia (cross-clamping). Blood samples will be obtained at 24 hours, 48 hours, and 72 hours after cross-clamping. Hourly urine output will be assessed as long as a Foley-catheter is in place.

Secondary outcomes

  1. Absolute and relative increase of serum creatinine concentration at 24 hours, 48 hours, and 72 hours after cardiac surgery ("cross clamping")

    Time frame: Pre-operative baseline day of surgery and 24 hours, 48 hours and 72 hours after induction of ischemia

  2. Incidence of AKI as defined by KDIGO until discharge

    Time frame: Pre-operative baseline day of surgery to day of discharge, an expected average of 10 days

  3. Occurrence of AKI according to KDIGO I, II, III

    Time frame: Pre-operative baseline day of surgery to day of discharge, an expected average of 10 days

  4. Maximum serum creatinine concentration detected postoperatively during hospitalization

    Time frame: Pre-operative baseline day of surgery to day of discharge, an expected average of 10 days

  5. Need for renal replacement treatment during hospitalization

    Time frame: Patient will be followed up for the duration of hospital stay, an expected average of 10 days

  6. In-hospital mortality

    Time frame: Patient will be followed up for the duration of hospital stay, an expected average of 10 days

  7. Length of hospital stay

    Time frame: Patient will be followed up for the duration of hospital stay, an expected average of 10 days

  8. Length of stay on intensive care unit (ICU)

    Time frame: Day of admittance until day of discharge from ICU, an expected average of 2 days

  9. tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) urine concentrations before surgery and at 4 hours and 24 hours after onset of ischemia (NephroCheck Test)

    Time frame: Pre-operative baseline day of surgery and at 4 hours and 24 hours after induction of ischemia

  10. C-reactive Protein (CRP) concentration

    Time frame: Pre-operative day of surgery and at 24 hours after onset of ischemia

  11. Leukocyte count

    Time frame: Pre-operative day of surgery and at 24 hours after onset of ischemia

  12. Creatine kinase concentration

    Time frame: Pre-operative day of surgery and at 24 hours after onset of ischemia

  13. Troponin T concentration

    Time frame: Pre-operative day of surgery and at 24 hours after onset of ischemia

  14. Lactate Dehydrogenase concentration

    Time frame: Pre-operative day of surgery and at 24 hours after onset of ischemia

  15. N-terminal Pro brain natriuretic peptide (NT-ProBNP) concentration

    Time frame: Pre-operative day of surgery and at 24 hours after onset of ischemia

  16. Lactate concentration

    Time frame: Pre-operative day of surgery and at 24 hours after onset of ischemia

  17. Amino acid pattern (concentrations), Insulin concentration, insulin-like growth factors (IGF1) concentration, glucose concentration

    Time frame: Before start of diet and on day of admission (before surgery)

  18. Mortality rate at 30 and 180 days (as followed-up upon by telephone call)

    Time frame: Day of surgery until 180 days after time point of surgery

  19. Need for renal replacement therapy within 180 days after time point of surgery (as followed-up upon by telephone call)

    Time frame: Day of surgery until 180 days after time point of surgery

Sponsors and collaborators

Lead sponsor

University of Cologne

Other

Collaborators

  • Fresenius Kabi

Registry information

Acronym: UNICORN

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Oct 23, 2018
Registry last updated
Apr 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.